Search results
Results from the WOW.Com Content Network
Cancer specific T-cells can be obtained by fragmentation and isolation of tumor infiltrating lymphocytes, or by genetically engineering cells from peripheral blood. The cells are activated and grown prior to transfusion into the recipient (tumor bearer).
A portion of the recipient's tumor tissue is removed during a surgical procedure prior to treatment. [3] The recipient's T cells (the tumor-infiltrating lymphocytes) are separated from the tumor tissue, multiplied and then infused into the patient in a single dose. [3] T cells are a type of cell that helps the immune system fight cancer and ...
Pages for logged out editors learn more. Contributions; Talk; Tumor-infiltrating lymphocyte
Important tumor regressions were observed in patients treated with IL-2 and very large numbers (≥10 10) of expanded TILs (tumor-infiltrating lymphocytes). [ 14 ] [ 15 ] Patients injected with expanded TILs directed against gp100 showed tumor regression but also significant adverse side effects such as uveitis .
Cancer specific T-cells can be obtained by fragmentation and isolation of tumour infiltrating lymphocytes, or by genetically engineering cells from peripheral blood. The cells are activated and grown prior to transfusion into the recipient (tumor bearer).
Tumor-infiltrating lymphocytes can become tumor-promoting due to the immunosuppressive mechanisms of the tumor microenvironment. [70] Cancer cells induce apoptosis of activated T cells by secreting exosomes containing death ligands such as FasL and TRAIL, and via the same method, turn off the normal cytotoxic response of natural killer cells ...
Cellular adoptive therapy is another alternative for these patients. The first studies with tumor-infiltrating lymphocytes (TILs) were performed at the Surgery Branch in the National Institutes of Health. These studies used TILs grown from different murine tumors and showed in vivo anti-tumor activity of these cells
The adoptive transfer of autologous tumor infiltrating lymphocytes (TIL) [27] [28] [29] or genetically re-directed peripheral blood mononuclear cells [30] [31] has been used experimentally to treat patients with advanced solid tumors, including melanoma and colorectal carcinoma, as well as patients with CD19-expressing hematologic malignancies ...